Exscientia appoints new leaders to strengthen the impact of integrated technologies and focus clinical development expertise in oncology

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. appointed to chief technology officer, john p. overington, ph.d., will assume strategic leadership over the company's technology solutions to further accelerate exscientia's ai-led drug design platform an.
EXAI Ratings Summary
EXAI Quant Ranking